Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, ...

TAIPEI, Taiwan I June 06, 2025 I OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies ...

PLAINSBORO, NJ, USA I June 6, 2025 I Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on ...

STOCKHOLM, Sweden I June 6, 2025 I Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 ...

Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to ...

Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety ...

LONDON, UK I June 02, 2025 I GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for ...

ROCKVILLE, MD, USA I June 5, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase ...

CHENGDU, China I June 5, 2025 I On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced ...

SHANGHAI, China and CHICAGO, IL, USA I June 5, 2025 I The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio ...

Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to ...

I On May 30, 2025, Conjustar Biologics announced that it's EphA2 targeting PDC drug SC-102 has received Investigational New Drug (IND) approval ...